Raloxifene temporarily reduces arterial stiffness

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 6, 2010, Pages 1229-1235

  Obayashi, Satoshi ^a   Terauchi, Masakazu ^a   Kato, Kiyoko ^a   Akiyoshi, Mihoko ^a   Kubota, Toshiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Arterial stiffness; Atherosclerosis; Cardio ankle vascular index (CAVI); Raloxifene

Indexed keywords

RALOXIFENE;

ADULT; AGE; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; RISK ASSESSMENT;

AGED; ANKLE BRACHIAL INDEX; ARTERIES; ATHEROSCLEROSIS; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; ELASTICITY; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78651278050     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01310.x     Document Type: Article

References (27)

1. Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998; 2: 508-511.
2. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000; 85: 2966-2969.
3. Saitta A, Altavilla D, Cucinotta D et al. Randomized, doubleblind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-1519.
4. Leitzbach D, Weckler N, Madajka M, Malinski T, Wiemer G, Linz W. Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats. Arzneimittelforschung 2005; 55: 86-92.
5. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 2002; 434: 141-149.
6. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: Effects of raloxifene administration. J Clin Endocrinol Metab 2003; 88: 2135-2140.
7. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15.
8. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation 2002; 106: 2085-2090.
9. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001; 21: 2046-2050.
10. Mattace-Raso FU, van der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam study. Circulation 2006; 113: 657-663.
11. Siasos G, Tousoulis D, Vlachopoulos C et al. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. Am J Hypertens 2009; 22: 586-592.
12. Yamabe T, Yoshida M, Saijyo Y et al. Brachio-ankle pulse wave velocity and cardio ankle vascular index (CAVI). Biomed Pharmacother 2004; 58: S95-S98.
13. Kadota K, Takamura N, Aoyagi K et al. Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. Circ J 2008; 72: 304-308.
14. Izuhara M, Shioji K, Kadota S et al. Relationship of cardioankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J 2008; 72: 1762-1767.
15. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/ arm blood pressure index. JAMA 1993; 270: 487-489.
16. Heald CL, Fowkes FG, Murray GD, Price JF. Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis 2006; 189: 61-69.
17. Wexler L, Brundage B, Crouse J et al. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation 1996; 94: 1175-1192.
18. Okumura T, Qatanabe S, KurataMet al. Relationship between Cardio-Ankle Vascular Index (CAVI) and Carotid Atherosclerosis in patients with essential hypertension. Hypertens Res 2008; 31: 2115-2127.
19. Tsang SY, Yao X, Essin K et al. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 2004; 35: 1709-1714.
20. Leung FP, Tsang SY, Wong CM et al. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol 2007; 34: 809-813.
21. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
22. da Costa LS, de Oliveira MA, Rubim VS et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453-1456.
23. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-857.
24. Collins P, Mosca L, Geiger MJ et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: Results of subgroup analyses by age and other factors. Circulation 2009; 119: 922-930.
25. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42: 698-704.
26. Melner MH, Abney TO. Depletion of the cytoplasmic estrogen receptor in gonadotropin-desensitized testes. Endocrinology 1980; 107: 1620-1626.
27. Jerez S, de Bruno MP, Coviello A. Endothelium-dependent desensitization to angiotensin II in rabbit aorta: The mechanisms involved. Can J Physiol Pharmacol 2001; 79: 481-489.